- Selected adults making a fully informed decision with a clinician
- People who understand uncertain benefit, false positives and follow-up burden
- Research participants in rigorous trials
Emerging
TEST PASSPORT · REVIEWED JULY 2026
Multi-cancer detection blood tests
Promising technology with unanswered mortality, false-positive and follow-up questions.MCD tests look for signals such as cancer-derived DNA across multiple cancers. They are being studied; none should replace established screening, and a positive result is not a diagnosis.
ACCESSLab drawVenous blood
TURNAROUNDSeveral weeksProvider and location dependent
RELATIVE COST$$$$Total downstream cost matters
COMMERCE STATUSEducation onlyNo direct checkout yet
HOW TO USE THIS PAGE
Decide whether this test deserves a place in your plan.
- 01Confirm the question
Be clear about what decision the result would change before ordering.
- 02Check fit and preparation
Review who it helps, who should pause and how to protect the quality of the signal.
- 03Plan the response
Know what you will do with a normal, abnormal or unclear result.
01 / WHO SHOULD TAKE IT
Fit the test to
the person.
Testing is useful when the result can change a real decision. These are educational selection criteria, not a diagnosis or personal order.- Replacing mammography, colonoscopy/FIT, cervical or lung screening
- Ruling out cancer after symptoms
- Anyone without a plan and resources for diagnostic follow-up
02 / SIGNAL VS. STORY
What it tells you.
What it cannot.
01
Whether the assay detected a cancer-associated signal
02
A predicted tissue of origin for some assays
03
The need for a diagnostic workup—not a cancer diagnosis
01
No definitive trial yet shows reduced overall cancer mortality
02
Performance varies by cancer and stage and is generally better for later-stage disease
03
False positives and difficult negative workups can cause harm, anxiety and cost
03 / MARKERS + RANGES
Read the panel
without chasing flags.
The report should show its own method, units and laboratory reference interval. Clinical decision thresholds may be different from a lab interval. We do not invent a universal “optimal” range where authoritative guidance does not support one.Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.
Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.
Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.
Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.
Use the laboratory unit and method, then interpret with symptoms, trend and the decision this marker can change.
MEN, WOMEN + LIFE-STAGE CONTEXT
The correct range is personal context—not pink versus blue numbers.
Where biology differs, we call it out. Clinical interpretation should also reflect organs present, hormone therapy, pregnancy, age, medications and health history.
A negative MCD result does not replace breast or cervical screening and does not rule out ovarian or other cancer.
A negative MCD result does not replace colorectal/lung pathways or prostate shared decision-making.
04 / PREPARATION
Protect the quality
of the signal.
The best assay cannot rescue the wrong timing, wrong specimen or wrong question. Follow the ordering clinician and laboratory instructions when they differ from this general guide.Confirm all standard screening remains scheduled regardless of the result.
Know who owns a positive result and what imaging/procedures may follow.
Ask for performance by stage and population—not one headline sensitivity.
REPEAT CADENCENo universally established interval. If used, frequency should follow the specific assay evidence and clinician guidance without displacing standard screening.
05 / AFTER THE RESULT
Turn the number
into a next step.
- 01
Positive means diagnostic workup, not treatment
- 02
Negative does not clear symptoms or cancel screening
- 03
Track downstream procedures and uncertainty
DO NOT WAIT ON A CONSUMER TEST
Concerning symptoms require diagnostic evaluation regardless of an MCD result
A positive result needs coordinated clinician-led follow-up
06 / MODERN BIO SELECT
Built for a responsible purchase path.
We will not turn uncertainty into urgency. Future listing requires transparent performance and a complete follow-up pathway.Multi-cancer detection blood tests
- Future format
- No direct checkout yet
- Price position
- High-cost emerging option
- Before checkout
- Eligibility · method · privacy · total cost · interpretation · abnormal-result routing
07 / SCIENTIFIC FOUNDATION